Myeloma

Patients with heavily pretreated myeloma tended to have “really amazing results” with the CAR-T cell therapy, Carvykti.

After cancer, I've been learning to maintain a positive attitude regarding my self-image and rehabilitation.

The Food and Drug Administration approved the CAR-T cell therapy, Carvykti, for previously treated patients with multiple myeloma.

The Food and Drug Administration approved Abecma for adults with relapsed or refractory multiple myeloma who have received two or more previous lines of therapy.

There is no difference in treatment for non-secretory multiple myeloma and multiple myeloma, an expert told CURE®.

Of everything I've ever done, I wonder how my multiple myeloma came to be.

An FDA committee voted that the benefits of Carvykti outweigh the risks for myeloma treatment, though concerns about secondary malignancies remain.

Here is a run-down of some topics we covered in the Spring 2024 issue of CURE.

Eating a plant-based diet has been associated with sustained MRD negativity for patients with multiple myeloma.

The BCMA protein has become the primary target for treating multiple myeloma, resulting in longer survival and more manageable side effects.

This poem was written in hope that those experiencing multiple myeloma, or other cancers, will find solace in knowing that advancements in treatments are being made every day, and a positive attitude with caregiver acceptance and support will prolong one’s days for a productive life.

Even though multiple myeloma had devastating effects on my collapsed lungs, singing has helped regain my sense of strength and resilience.

Most patients with relapsed or refractory multiple myeloma responded to treatment with the CAR-T cell therapy, Carvykti, according to a small study.

The Food and Drug Administration is reviewing the novel drug, linvoseltamab, for the treatment of patients with pretreated, relapsed or refractory multiple myeloma.

The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.

From the San Francisco 49ers’ Trent Williams looking back on his cancer experience to a Republican congressman returning to work after myeloma treatment, here’s what’s happening in the oncology space this week.

Patients with relapsed or refractory multiple myeloma had lower progressive disease outcomes when receiving Blenrep with Velcade and dexamethasone, research found.

The Food and Drug Administration is requesting that CAR-T cell therapies now come with a Boxed Warning about secondary malignancies that have been reported in patients who undergo these treatments.

Financial burdens from medical costs negatively affect quality of life in patients who have received stem cell transplants, recent research showed.

The novel drug, IDP-023, is being investigated in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma.

A treatment combination of Sarclisa, Kyprolis, Revlimid and dexamethasone demonstrated a complete response in patients who were newly diagnosed with multiple myeloma.

Study findings support the use of a financial navigation program, in hopes of aiding patients with multiple myeloma affected by financial toxicity.

A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.

The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens.

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma.

I didn't know that a side effect of bone strengtheners could be jawbone detachment.

An expert discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.

The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.

I found family in my cancer support groups.